<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552706</url>
  </required_header>
  <id_info>
    <org_study_id>LL2014006</org_study_id>
    <nct_id>NCT02552706</nct_id>
  </id_info>
  <brief_title>The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis</brief_title>
  <official_title>The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Bao'an Maternal and Child Health Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Sixth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital Of Baoan District, Shenzhen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shenzhen Bao'an Maternal and Child Health Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and its mechanisms of oral mixture
      probiotics in preventing necrotizing enterocolitis among the preterm very low birth weight
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Necrotizing enterocolitis (NEC) remains the most catastrophic gastrointestinal emergencies in
      preterm very low birth weight (VLBW) infants.Although study showed it is a multifactorial
      disease, its pathogenesis is still not yet unclear currently. Prematurity and formula feeding
      is considered as the main risk factors.Gut microbiota disturbance and immature immune system
      is associated with NEC. A lot of studies had showed that oral probiotics can alter gut
      microbiota flora colonization and reduce the incidence of NEC,but the exact mechanism remains
      unclear.The aim of this study is to elucidate the clinical efficacy and possible molecular
      mechanism of oral mixture probiotics in preventing NEC among preterm VLBW infants.

      Patient Registry procedures: First,randomized numbers was generated by the computer and sent
      to the principal investigator(PI) at each center when an infant was eligible for
      enrollment.Second, patient will be assigned randomly to experimental group or control group
      by PI.Finally,the PI at each center will be responsible for the accuracy,completeness or
      representativeness of medical records, registry forms,data collection.

      Sample size determination: The incidence of death and NEC was around 20% recently.To reduce
      the incidence of NEC and death to 10% at discharge would require a 50% improvement.At 80%
      power at P = 0.05 (two-sided),the loss rate of 0.2, this would require 135 subjects per arm.

      Statistical analysis:The two groups were compared by a Χ2-test for categorical
      variables,Mann-Whitney U Test were used when reporting medians.A P value of &lt;0.05 was
      considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of combined death and necrotizing enterocolitis</measure>
    <time_frame>at 36 weeks correct gestational age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the incidence of sepsis,intraventricular hemorrhage(IVH)(grade 3-4),feeding intolerance(FI),bronchopulmonary dysplasia(BPD),parenteral nutrition associated liver disease(PNALD)and retinopathyof prematurity(ROP).</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 8 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>the influence of oral probiotics on gut microbiota and immunomodulatory</measure>
    <time_frame>at birth, 2 and 4 weeks of life, 36 week correct gestational age.</time_frame>
    <description>test fecal microbiota via high throughput sequencing and blood toll like receptor(TLR)2,TLR4,neclear factor kappa B(NF-KB)were detected using flow cytomtry.Inflammatory factors of blood were tested via Cytometric Bead Array(CBA).All above samples were obtained only from Shenzhen Bao'an Maternal and Child Health Hospital.The fecal DNA were first extracted at centre laboratory in aboved hospital and sent them to Beijing Genomics Institute(BGI) for further sequenceing ,if necessary, quantitative polymerase chain reaction(qPCR)of gut dominant bacterias related to late onset sepsis(LOS) will be tested for assessing the effect of oral probiotics on gut microbiota and underlying the mechanism. Flow cytometry analysis of TLR2,TLR4 and NF-KB were made by the senior laboratorian of our department and resposible for the accuracy of experimental result. CBA of inflammatory factors will be made by senting the blood samples to Beijing JIAMAY BIOLAB.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <condition>Death</condition>
  <arm_group>
    <arm_group_label>probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotics</intervention_name>
    <description>Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.</description>
    <arm_group_label>probiotics group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glucose solution</intervention_name>
    <description>Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants ≦ 34 weeks gestational age and birth weight below 1500 gm and who
             survive to NICU are eligible for the trial.

        Exclusion Criteria:

          -  severe asphyxia (stage III),

          -  fetal chromosomal anomalies,

          -  cyanotic congenital heart disease,

          -  congenital intestinal atresia, gastroschisis, omphalocele, active upper gastric
             intestinal bleeding,

          -  lacking/refused of parental consent,

          -  those who are fasted for &gt;3 weeks during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuefeng Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Bao'an Maternal and Child Health Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HungChih Lin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benqing Wu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shenzhen People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaodong Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shenzhen Sixth People's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhangxin Wang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Longhua Hospital Of Baoan District, Shenzhen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuefeng Li, M.D.</last_name>
    <phone>86+13751029103</phone>
    <email>liyuefeng111@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Longhua People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shenzhen Bao'an Maternal and Child Health Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuefeng Li, M.D.</last_name>
      <phone>+86-13751029103</phone>
      <email>liyuefeng111@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benqing Wu, M.D.</last_name>
      <phone>+86-13902436593</phone>
      <email>wubenqing783@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Sixth People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lin HC, Hsu CH, Chen HL, Chung MY, Hsu JF, Lien RI, Tsao LY, Chen CH, Su BH. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008 Oct;122(4):693-700. doi: 10.1542/peds.2007-3007.</citation>
    <PMID>18829790</PMID>
  </reference>
  <results_reference>
    <citation>Genzel-Boroviczény O, MacWilliams S, Von Poblotzki M, Zoppelli L. Mortality and major morbidity in premature infants less than 31 weeks gestational age in the decade after introduction of surfactant. Acta Obstet Gynecol Scand. 2006;85(1):68-73.</citation>
    <PMID>16521683</PMID>
  </results_reference>
  <results_reference>
    <citation>Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012 Jun 9;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.</citation>
    <PMID>22682464</PMID>
  </results_reference>
  <results_reference>
    <citation>Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2007 May;92(3):F193-8. Epub 2006 Sep 19. Review.</citation>
    <PMID>16984980</PMID>
  </results_reference>
  <results_reference>
    <citation>Huda S, Chaudhery S, Ibrahim H, Pramanik A. Neonatal necrotizing enterocolitis: Clinical challenges, pathophysiology and management. Pathophysiology. 2014 Feb;21(1):3-12. doi: 10.1016/j.pathophys.2013.11.009. Epub 2014 Feb 11.</citation>
    <PMID>24525171</PMID>
  </results_reference>
  <results_reference>
    <citation>Hall NJ, Eaton S, Pierro A. Royal Australasia of Surgeons Guest Lecture. Necrotizing enterocolitis: prevention, treatment, and outcome. J Pediatr Surg. 2013 Dec;48(12):2359-67. doi: 10.1016/j.jpedsurg.2013.08.006. Review.</citation>
    <PMID>24314171</PMID>
  </results_reference>
  <results_reference>
    <citation>Quigley MA, Henderson G, Anthony MY, McGuire W. Formula milk versus donor breast milk for feeding preterm or low birth weight infants. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002971. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD002971.</citation>
    <PMID>17943776</PMID>
  </results_reference>
  <results_reference>
    <citation>Mshvildadze M, Neu J, Mai V. Intestinal microbiota development in the premature neonate: establishment of a lasting commensal relationship? Nutr Rev. 2008 Nov;66(11):658-63. doi: 10.1111/j.1753-4887.2008.00119.x. Review.</citation>
    <PMID>19019028</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma R, Tepas JJ 3rd, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, Premachandra BR. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg. 2007 Mar;42(3):454-61.</citation>
    <PMID>17336180</PMID>
  </results_reference>
  <results_reference>
    <citation>Nair V, Soraisham AS. Probiotics and prebiotics: role in prevention of nosocomial sepsis in preterm infants. Int J Pediatr. 2013;2013:874726. doi: 10.1155/2013/874726. Epub 2013 Jan 14.</citation>
    <PMID>23401695</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarowska J, Choroszy-Król I, Regulska-Ilow B, Frej-Mądrzak M, Jama-Kmiecik A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases. Adv Clin Exp Med. 2013 Sep-Oct;22(5):759-66. Review.</citation>
    <PMID>24285463</PMID>
  </results_reference>
  <results_reference>
    <citation>Di Gioia D, Aloisio I, Mazzola G, Biavati B. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants. Appl Microbiol Biotechnol. 2014 Jan;98(2):563-77. doi: 10.1007/s00253-013-5405-9. Epub 2013 Nov 28. Review.</citation>
    <PMID>24287935</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine. Am J Physiol Gastrointest Liver Physiol. 2012 Mar 15;302(6):G608-17. doi: 10.1152/ajpgi.00266.2011. Epub 2011 Dec 29.</citation>
    <PMID>22207578</PMID>
  </results_reference>
  <results_reference>
    <citation>Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010 May;125(5):921-30. doi: 10.1542/peds.2009-1301. Epub 2010 Apr 19.</citation>
    <PMID>20403939</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu P, Sodhi CP, Hackam DJ. Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis. Pathophysiology. 2014 Feb;21(1):81-93. doi: 10.1016/j.pathophys.2013.11.007. Epub 2013 Dec 22.</citation>
    <PMID>24365655</PMID>
  </results_reference>
  <results_reference>
    <citation>Hackam DJ, Afrazi A, Good M, Sodhi CP. Innate immune signaling in the pathogenesis of necrotizing enterocolitis. Clin Dev Immunol. 2013;2013:475415. doi: 10.1155/2013/475415. Epub 2013 May 23. Review.</citation>
    <PMID>23762089</PMID>
  </results_reference>
  <results_reference>
    <citation>Ganguli K, Meng D, Rautava S, Lu L, Walker WA, Nanthakumar N. Probiotics prevent necrotizing enterocolitis by modulating enterocyte genes that regulate innate immune-mediated inflammation. Am J Physiol Gastrointest Liver Physiol. 2013 Jan 15;304(2):G132-41. doi: 10.1152/ajpgi.00142.2012. Epub 2012 Nov 8.</citation>
    <PMID>23139215</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>March 26, 2016</last_update_submitted>
  <last_update_submitted_qc>March 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Bao'an Maternal and Child Health Hospital</investigator_affiliation>
    <investigator_full_name>liyuefeng</investigator_full_name>
    <investigator_title>Ward chief of department of neonatology</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>preterm very low birth weight infants</keyword>
  <keyword>necrotizing enterocolitis</keyword>
  <keyword>gut microflora</keyword>
  <keyword>TLR</keyword>
  <keyword>NF-KB</keyword>
  <keyword>inflammatory factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

